These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36699438)

  • 1. Successful Treatment Of Acquired Hemophilia A Using FEIBA Supplemented With Emicizumab.
    Kaunchale N; Ansari S; More A; Bansal S; Kshirsagar S; Padate B; Rangarajan S; Shetty S
    Indian J Hematol Blood Transfus; 2023 Jan; 39(1):159-160. PubMed ID: 36699438
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention.
    Dane KE; Lindsley JP; Streiff MB; Moliterno AR; Khalid MK; Shanbhag S
    Res Pract Thromb Haemost; 2019 Jul; 3(3):420-423. PubMed ID: 31294330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study.
    Ettingshausen CE; Hermans C; Holme PA; Cid AR; Khair K; Oldenburg J; Négrier C; Botha J; Lelli A; Windyga J
    Ther Adv Hematol; 2023; 14():20406207231184323. PubMed ID: 37529276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring the bioavailability of FEIBA with a thrombin generation assay.
    Váradi K; Negrier C; Berntorp E; Astermark J; Bordet JC; Morfini M; Linari S; Schwarz HP; Turecek PL
    J Thromb Haemost; 2003 Nov; 1(11):2374-80. PubMed ID: 14629472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.
    Shima M; Amano K; Ogawa Y; Yoneyama K; Ozaki R; Kobayashi R; Sakaida E; Saito M; Okamura T; Ito T; Hattori N; Higasa S; Suzuki N; Seki Y; Nogami K
    J Thromb Haemost; 2023 Mar; 21(3):534-545. PubMed ID: 36696195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emicizumab for the prevention of bleeds in hemophilia A.
    Mahlangu J
    Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297
    [No Abstract]   [Full Text] [Related]  

  • 7. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
    Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
    J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary Embolism in Acquired Hemophilia A: A Rare Complication With Factor VIII Inhibitor Bypassing Activity Therapy.
    Aslam HM; Chong T; Park J; Nicolosi T; Shah R
    Cureus; 2020 Jul; 12(7):e9152. PubMed ID: 32789089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
    Takeyama M; Matsumoto N; Abe H; Harada S; Ogiwara K; Furukawa S; Shimonishi N; Nakajima Y; Yada K; Soeda T; Nogami K
    Pediatr Blood Cancer; 2023 Oct; 70(10):e30590. PubMed ID: 37467119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group.
    Pfrepper C; Klamroth R; Oldenburg J; Holstein K; Eichler H; Hart C; Moehnle P; Schilling K; Trautmann-Grill K; Alrifai M; Ay C; Miesbach W; Knoebl P; Tiede A
    Hamostaseologie; 2023 Dec; ():. PubMed ID: 38049124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab.
    Kizilocak H; Marquez-Casas E; Malvar J; Young G
    Haemophilia; 2023 Jan; 29(1):100-105. PubMed ID: 36287631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
    Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.
    Bitrán R; Peña C; Arpón P; Loayza N; Salas K; Del Villar C; Chumpitaz G; Salinas V
    Medwave; 2022 Mar; 22(2):e8703. PubMed ID: 35323824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis.
    Garcia J; Hammer MR; Zia A
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102238. PubMed ID: 38053983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report.
    Al-Banaa K; Alhillan A; Hawa F; Mahmood R; Zaki A; El Abdallah M; Zimmerman J; Musa F
    Am J Case Rep; 2019 Jul; 20():1046-1048. PubMed ID: 31318850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of emicizumab in acquired hemophilia A: A case report.
    Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
    Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab in tolerized patients with hemophilia A with inhibitors: A single-institution pediatric cohort assessing inhibitor status.
    Batsuli G; Greene A; Meeks SL; Sidonio RF
    Res Pract Thromb Haemost; 2021 Feb; 5(2):342-348. PubMed ID: 33733033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile.
    Abarca-Villaseca V; Soto-Arellano V
    Am J Case Rep; 2021 Apr; 22():e929598. PubMed ID: 33883542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate).
    Negrier C; Voisin S; Baghaei F; Numerof R; Novack A; Doralt JE; Romanov V; Gringeri A;
    Blood Coagul Fibrinolysis; 2016 Jul; 27(5):551-6. PubMed ID: 26829366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.
    Ebbert PT; Xavier F; Seaman CD; Ragni MV
    Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.